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Abstract
Background: Human Epidermal Growth Factor Receptor 2 (HER-2; also known as erbB-2 or
neu), a proto-oncogene of the receptor tyrosine kinase superfamily, has been associated with
carcinogenesis and prognosis of human cancers, acting as a binding partner of other epidermal
growth factor receptor (EGFR) family in the activation of EGFR signaling. Amplification of the HER-
2 gene has been reported in lung cancer, where it has been associated with poor prognosis. In this
study, we investigated whether the four polymorphisms (-3444C>T, -1985 G>T, I655A A>G and
P1170A C>G) of the HER-2 gene are associated with the risk of lung cancer in Korean populations.
Methods:  The frequencies of 4 polymorphisms of the HER-2 gene were examined by the
polymerase chain reaction-restriction fragment length polymorphism or the single-nucleotide
polymorphism-identification technology assay in the 407 lung cancer patients and 407 healthy
controls.
Results: The frequencies of the 4 polymorphisms were not significantly different between patient
and control groups in overall subjects. However, in the subgroup analysis, the 3 single nucleotide
polymorphisms (-3444C>T, -1985G>T and P1170A C>G) showed statistically significant
differences in the subgroups of females, non-smokers, and non-drinkers (p < 0.05). Additionally, we
found the association between the risk of lung cancer and the polymorphisms of HER-2 gene in
non-smoker subgroups with adenocarcinoma (p < 0.05).
Conclusion: Our results suggest that the polymorphisms of the HER-2 gene are associated with
an increased susceptibility to lung cancer in females, non-smokers and non-drinkers subgroups in
the Korean population.
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Background
Lung cancer is the worldwide leading cause of cancer-
related death [1]. During the past decades, the rate of inci-
dence and mortality of lung cancer in Korea have been
increasing significantly and constantly[2]. Although lung
cancer has been considered as a disease caused by smok-
ing and environmental/occupational exposure, previous
studies suggest that genetic factors may also contribute to
the risk of lung cancer [3].
Single nucleotide polymorphisms (SNPs) are the most
common form of human genetic variation, and they may
contribute to an individual's susceptibility to cancer [4,5].
Many previous studies have demonstrated that some pol-
ymorphisms of certain genes are associated with the risk
of lung cancer, affecting either the gene expression or
activities of enzymes [6-8].
The HER-2 (also known as erbB-2 or neu and a member
of the epidermal growth factor receptor family), proto-
oncogene is located at chromosome 17q21 and encodes a
transmembrane glycoprotein (p185) with tyrosine kinase
activity [9,10]. Somatic mutations in the HER-2 gene have
not been observed in humans, however amplification and
overexpression of the HER-2 protein occur in lung cancer
and contribute to poor prognosis [11-13]. Recently, sev-
eral polymorphisms of the HER-2 gene have been depos-
ited in public databases http://www.ncbi.nlm.nih.gov/
SNP. Previous studies have suggested functional implica-
tions of the polymorphisms by showing that the polymor-
phisms of the HER-2 gene might result in increased
autophosporylation and tyrosine kinase activation
[14,15]. It is possible that the polymorphisms are associ-
ated with lung cancer, modulating the susceptibility to
disease.
To test this hypothesis, we performed a case-control study
to evaluate the association between the polymorphisms of
the HER-2 gene and the risk of lung cancer in the Korean
population.
Methods
Study subjects
All 814 study subjects were recruited between August
2001 and June 2005, including 407 lung cancer patients
recruited from the patient pool at the Genomic Research
Center for Lung and Breast/Ovarian Cancers (Seoul,
Korea) and Inha University Medical Center (Incheon,
Korea). The histological classification and staging of all
lung cancer cases was performed by pathological evalua-
tion at the time of diagnosis. 407 control subjects ran-
domly selected from a pool of healthy volunteers who had
visited the Cardiovascular Genome Center (Seoul, Korea),
Genome Research Center for Allergy and Respiratory Dis-
ease (Seoul, Korea), and Keimyung University Dongsan
Medical Center (Daegu, Korea). Detailed information on
diet, smoking status, drinking status, lifestyle, and medi-
cal history were collected by a trained interviewer using a
structured questionnaire. This study was also approved by
the institutional review board of participating institutes,
and a written informed consent was obtained from each
participant.
Selection of the polymorphisms for the HER-2 gene
6 SNPs of HER-2 gene were chosen in the promoter
regions (-3444 C>T, -3396 C>T, -3374 A>G, -1985 G>T)
and 2 SNPs in the coding regions (I655A A>G and
P1170A C>G) (Fig. 1a). -3444 C>T, -3396 C>T, -3374
A>G, and -1985 G>T polymorphism was found by the
direct-sequencing for the region spanning ~4kb upstream
from the translation initiation site (NM_004448) of HER-
2 gene in a small set of 24 lung cancer cases. I655A A>G
and P1170A C>G polymorphisms were selected by
reviewing the previous reports in the Korean population
[16,17].
Genotyping
Genomic DNA was prepared from 814 peripheral blood
samples using Puregene blood DNA kit (Gentra, Minne-
apolis, MN). Polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP) and single-
nucleotide polymorphism-identification technology
(SNP-IT) assay were performed for genotyping of HER-2
polymorphisms.
Genotyping of -1985 G>T and I655V A>G SNPs was car-
ried out by PCR-RFLP. The PCR primer sequences for -
1985 SNP were: forward, 5'-ACC CCA GCA TAG TAT GTC
AGA TG-3', and reverse, 5'-ATC CTA GGG AGT TGA GAA
ACA GG-3'. The PCR products were digested by Xmn I and
resolved by gel electrophoresis. The I655V SNP was ana-
lyzed as described previously [18].
-3444 C>T and P1170 C>G SNPs genotyping was per-
formed by SNP-IT assay using the SNP stream 25 K System
(Orchid Biosciences, Princeton, NJ). Briefly, the genomic
DNA region spanning the polymorphic site was PCR-
amplified using one phosphothiolated primer and one
regular PCR primers. The amplified PCR products were
then digested with exonuclease. The phosphothioated
strand of the PCR product was protected from exonucle-
ase digestion, generating a single-stranded PCR template.
The single-stranded PCR template was overlaid on a 384-
well plate that contained a covalently attached SNP-IT
extension primer which was designed to hybridize imme-
diately adjacent to the polymorphic site. The SNP-IT
primer was extended for a single base with DNA polymer-
ase and a mixture of appropriate dideoxynucleotide
tagged with either fluorescein isothiocyanate (FITC) or
biotin. The identity of the incorporated nucleotide wasBMC Cancer 2008, 8:359 http://www.biomedcentral.com/1471-2407/8/359
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determined by serial colorimetric reactions with anti-
FITC-alkaline phosphatase and streptavidin-horse radish
peroxidase, resulting blue and/or yellow color develop-
ments were analyzed with an ELISA reader and the final
genotyping (allele) calls were made with the QCReview
program.
Statistical analysis
Genotype frequencies and departures of genotype distri-
butions from the Hardy-Weinberg equilibrium for each
SNP were analyzed using the chi-square test or Fisher's
exact test. Pairwise LD for calculating D' and r2 was evalu-
ated as described previously [19]. Linkage disequilibrium
(LD) values were estimated using the Haploview version
3.32 http://www.broad.mit.edu/mpg/haploview. A pair
of SNPs is defined to have "strong linkage disequilibrium"
if the one-sided upper 95% confidence interval (95% CI)
boundary on D' is >0.98 and the lower boundary is >0.7.
Conversely, SNP pairs are said to have "strong evidence of
historical recombination" if the upper CI boundary on D'
is <0.9. Genotype-specific risks were estimated as odds
ratios with associated 95% confidence intervals by uncon-
ditional logistic regression (SAS Institute, Cary, NC) and
adjusted for age and gender. The p-value of < 0.05 was
considered statistically significant. Unconditional logistic
regression analysis was used to calculate odds ratios (ORs)
and 95% confidence intervals (CIs) for overall lung can-
cer, with adjustment gender and age. In addition to the
overall association analysis, we performed a stratified
analysis by age (median age, = 60 years/>60 years), gen-
der, smoking status, drinking status and tumor histology
to further explore the association between HER-2 geno-
types and the risk of lung cancer in each stratum. The ORs
and 95% CIs in the stratification analyses were calculated
using unconditional logistic regression analysis, with
adjustment for gender and age, when appropriate.
Results
We investigated the relationship between polymorphisms
of HER-2 and the risk of lung cancer in a case-control
study of 814 age-gender matched case and control sub-
jects. The distributions of age, gender, smoking status and
drinking status of every subject are summarized in Table
1. There were no differences in median age and gender
Distribution of HER-2 polymorphism Figure 1
Distribution of HER-2 polymorphism. (a) The locations of the six SNPs used in the HER-2 genotyping analysis [vertical 
arrows (numbered 1 to 6 from 5' to 3'): 1, rs2643194; 2, rs2517951; 3, rs2643195; 4, rs2934971; 5, rs1801200; 6, rs1058808]. 
The translation start site is marked with right-angled arrow at +1. Exons are dipicted as small blocks. (b) The pairwise measure 
of linkage disequilibrium (LD) between the six SNPs in (a) with D' statistics (values in the bottom left area of the table). The 
pairs exhibiting a strong linkage disequilibrium pattern are shaded. Especially, the three SNPs (numbered in 1, 2, 3) are in com-
pleted LD. r2 values are shown on the top right area of the table.BMC Cancer 2008, 8:359 http://www.biomedcentral.com/1471-2407/8/359
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Table 1: Demographic characteristics of case-control study population
Characteristics Controls Cases p-value
1. Age n = 407 n = 407
Median age 60.8 60.8
Range 30 – 84 30 – 78
2. Gender, n, (%) n = 407, (%) n = 407, (%)
Male 302, (74.2) 303, (74.5) 0.94
Female 105, (25.8) 104, (25.6)
3. Smoking status, n, (%) n = 309, (%) n = 396, (%)
Non-smoker 162, (52.4) 108, (27.3) <0.0001
Smoker 147, (47.6) 288, (72.7)
4. Drinking status, n, (%) n = 224, (%) n = 310, (%)
Non-drinker 78, (34.8) 118, (38.1) 0.44
Drinker 146, (65.2) 192, (61.9)
5. Histological cell type, n, (%) N = 388, (%)
Adenocarcinoma 157, (40.5)
Squamous cell 123, (31.7)
Small cell 79, (20.4)
Other carcinomaa 29, (7.5)
a Large cell, mixed cell carcinomas or undifferentiated carcinoma
Table 2: Genotyping frequencies for HER-2 in cases and controls and their association with risk of overall lung cancer
Genotype Case
(n = 407)
Control
(n = 407)
asOR (95% CI)a p-value
-3444 C>T CC 141 140 1
CT 201 205 0.97 (0.72 – 1.32) 0.86
TT 65 62 1.04 (0.68 – 1.58) 0.85
CT+TT 266 267 0.99 (0.74 – 1.32) 0.94
CC+CT 342 345 1
TT 65 62 1.06 (0.72 – 1.55) 0.77
-1985 G>T GG 144 140 1
GT 196 205 0.93 (0.69 – 1.26) 0.64
TT 67 62 1.05 (0.69 – 1.59) 0.82
GT+TT 263 267 0.96 (0.72, 1.28) 0.77
GG+GT 340 345 1
TT 67 62 1.10 (0.75-1.60) 0.63
I655V A>G AA 304 300 1
AG 97 97 0.99 (0.71 – 1.36) 0.93
GG 5 6 0.82 (0.25 – 2.72) 0.75
AG+GG 102 103 0.98 (0.71 – 1.34) 0.88
AA+AG 401 397 1
GG 5 6 0.83 (0.25 – 2.73) 0.75
P1170A C>G CC 144 137 1
CG 199 206 0.92 (0.68 – 1.25) 0.59
GG 64 64 0.95 (0.63 – 1.45) 0.82
CG+GG 263 270 0.93 (0.69 – 1.24) 0.61
CC+CG 343 343 1
GG 64 64 1.00 (0.69 – 1.46) 1
OR, odds ratio; CI, confidence interval.
aasOR are adjusted for age and gender.BMC Cancer 2008, 8:359 http://www.biomedcentral.com/1471-2407/8/359
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between cases and controls. However, smoking status and
drinking status were missing in some patients. These dif-
ferences were controlled in the later logistic regression
analysis with adjusted gender and age.
In this study, we have chosen 4 SNPs in the promoter
regions (-3444 C>T, -3396 C>T, -3374 A>G, -1985 G>T)
and 2 SNPs in the coding regions (I655A A>G and
P1170A C>G) of the HER-2 gene (Figure 1a). Interest-
ingly, the 3 SNPs (-3444 C>T, -3396 C>T and -3374 A>G)
in the promoter regions showed a complete linkage dise-
quilibrium (LD) (D' = 1)(Figure 1b). These results imply
that the 3 polymorphisms are a SNP block. We represent-
atively showed the data of -3444C>T for the 3 SNPs (-
3444 C>T, -3396 C>T and -3374 A>G) in the following
results. Therefore, we only performed genotyping for the
4 SNPs (-3444 C>T, -1985 G>T, I655A A>G and P1170A
C>G). Therefore, we only performed genotyping for the 4
SNPs (-3444 C>T, -1985 G>T, I655A A>G and P1170A
C>G) in all study subjects (407 case including the previ-
ous 24 case samples and 407 controls).
The frequencies of the 4 SNPs (-3444 C>T, -1985 G>T,
I655A A>G and P1170A C>G) in the total lung cancer and
healthy-control subjects are shown in Table 2. The distri-
butions of the 4 SNPs in the cases and controls were in
Hardy-Weinberg equilibrium. There were no significant
differences between the 4 polymorphisms of the HER-2
and the risk of lung cancer in all subjects (Table 2). How-
ever, in the subgroup analysis, there were statistically sig-
nificant differences between the genotype frequencies of
the 3 SNPs (-3444 C>T, -1985 G>T and P1170A C>G) and
the risk of lung cancer (Table 3, 4 and 5, Additional File
1). In females, -3444 TT and -1985 TT genotypes exhibited
increased risk of lung cancer (Table 3). In non-smokers
and non-drinkers, -3444 TT, -1985 TT and P1170A GG
genotypes showed higher risk of lung cancer than other
genotypes of the SNPs and the differences were more mag-
nified after adjustment for age and gender (Table 4 and 5).
Furthermore, we additionally performed the statistical
analysis to demonstrate whether the polymorphisms are
associated with tumor histology in the subgroups. We
found that-3444 TT and -1985 TT genotypes exhibited the
increased risk of lung cancer in non-smokers group with
adenocarcinoma, adjusting with gender and age (Table 6).
Hence, our results demonstrated that the 3 SNPs of HER-
2 were associated with the risk of lung cancer in females,
non-smokers, non-drinkers and tumor histology.
Discussion
In this study, we investigated whether the polymorphisms
of the HER-2 gene were associated with the risk of lung
Table 3: Comparative analysis between genotype frequencies and the risk of lung cancer in the subgroups of females
Female Genotype Cases
(n = 104)
Controls
(n = 105)
OR (95% CI) p-value asOR (95% CI)a p-value
-3444 C>T CC 35 39 1 1
CT 50 58 0.96 (0.53 – 1.74) 0.89 0.94 (0.51 – 1.72) 0.85
TT 19 8 2.65 (1.03 – 6.80) 0.04 2.23 (0.85 – 5.84) 0.10
CT+TT 69 66 1.17 (0.66 – 2.06) 0.60 1.11 (0.62 – 1.98) 0.73
CC+CT 85 97 1 1
TT 19 8 2.71 (1.13 – 6.51) 0.03 2.31 (0.95 – 5.64) 0.07
-1985 G>T GG 36 39 1 1
GT 49 57 0.93 (0.52 – 1.68) 0.81 0.93 (0.51 – 1.70) 0.81
TT 19 9 2.29 (0.92 – 5.70) 0.08 1.93 (0.76 – 4.91) 0.17
GT+TT 68 66 1.12 (0.63 – 1.97) 0.70 1.07 (0.60 – 1.92) 0.81
GG+GT 85 96 1 1
TT 19 9 2.38 (1.02 – 5.55) 0.04 2.02 (0.85 – 4.78) 0.11
P1170A C>G CC 37 37 1 1
CG 49 58 0.85 (0.47 – 1.53) 0.58 0.84 (0.46 – 1.55) 0.59
GG 18 10 1.80 (0.73 – 4.42) 0.20 1.57 (0.63 – 3.91) 0.34
CG+GG 67 68 0.99 (0.56 – 1.74) 0.96 0.96 (0.53 – 1.72) 0.88
CC+CG 86 95 1 1
GG 18 10 1.99 (0.87 – 4.54) 0.10 1.73 (0.75 – 4.02) 0.20
OR, odds ratio; CI, confidence interval.
aasOR are adjusted for age.BMC Cancer 2008, 8:359 http://www.biomedcentral.com/1471-2407/8/359
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cancer in the Korean population. Although the distribu-
tion of the polymorphisms of the HER-2 gene did not dis-
play statistically significant associations with all lung
cancer and control subjects, the 3 polymorphisms (-3444
C>T, -1985 G>T and P1170A C>G) of HER-2 gene were
found to be associated with the risk of lung cancer in
female, non-smoker and non-drinker subgroups.
The previous studies on SNPs of the HER-2 gene have
mainly been focused on breast cancer [14,18,20]. In the
Korean population, Han et al. [16] showed that the poly-
morphisms of the HER-2 gene are associated with HER-2
protein expression and disease outcome in breast cancer.
On the other hand, there are some reports to show that
overexpression of HER-2 is an independent prognostic
factor of survival and to be a combinatorial target in lung
cancer, using an EGFR tyrosine kinase inhibitor together
with HER-2 dimerization inhibitors [12,13,21]. Although
cigarette smoking is the most important risk factor of lung
cancer, previous studies have suggested differences in epi-
demiologic characteristics and environmental subtypes,
suggesting an existence of non-tobacco related risk factors
in the pathogenesis of lung cancer [22-24]. Alcohol con-
sumption is an established risk factor for cancers of the
oral cavity, pharynx, larynx, esophagus, and liver [25]. The
associations between alcohol drinking and lung cancer
risk have also been reported [26,27]. Moreover, somatic
mutations of EGFR and HER-2 were preferentially identi-
fied in Oriental ethnicity compared with other ethnicities,
female gender compared with male gender and never
smokers compared with smokers, showing clinical
responses to treatment [28-30]. Among the total 407 lung
cancer patients, 89 patients were female and non-smoker
in this study. Interestingly, about 72% (64/89) of non-
smoker, female lung cancer patients were diagnosed as
adenocarcinoma. We showed significant association
between the polymorphisms and adenocarcinoma in the
subgroups. Our results, therefore, suggest that the poly-
morphisms of the HER-2 gene might contribute to the
susceptibility of female, non-smoker and non-drinker
subgroups in the Korean population to lung cancer as
EGFR mutations. However, the significant difference of
the polymorphisms in females disappeared after adjust-
ment for age. These discrepant results might be caused by
the small number of young women in our study subjects
[31]. Thus, our results need to be confirmed in future with
a larger sample size of young women.
Table 4: Comparative analysis between genotype frequencies and the risk of lung cancer in the subgroups of non-smokers
Non-smoker Genotype Cases
(n = 108)
Controls
(n = 162)
OR (95% CI) p-value asOR (95% CI)b p-value
-3444 C>T CC 36 61 1 1
CT 48 83 0.98 (0.57 – 1.69) 0.94 0.99 (0.56 – 1.74) 0.96
TT 24 18 2.26 (1.08 – 4.72) 0.03 2.67 (1.20 – 5.91) 0.02
CT+TT 72 101 1.21 (0.73 – 2.01) 0.47 1.25 (0.73 – 2.14) 0.41
CC+CT 84 144 1 1
TT 24 18 2.29 (1.17 – 4.46) 0.02 2.69 (1.30 – 5.56) 0.01
-1985 G>T GG 37 61 1 1
GT 47 82 0.94 (0.55 – 1.63) 0.84 0.97 (0.55 – 1.71) 0.91
TT 24 19 2.08 (1.01 – 4.31) 0.05 2.41 (1.10 – 5.27) 0.03
GT+TT 71 101 1.16 (0.70 – 1.93) 0.57 1.21 (0.71 – 2.07) 0.48
GG+GT 84 143 1 1
TT 24 19 2.15 (1.11 – 4.16) 0.02 2.46 (1.20 – 5.01) 0.01
P1170A C>G CC 37 58 1 1
CG 48 84 0.90 (0.52 – 1.54) 0.69 0.89 (0.50 – 1.57) 0.68
GG 23 20 1.80 (0.87 – 3.73) 0.11 2.05 (0.94 – 4.47) 0.07
CG+GG 71 104 1.07 (0.64 – 1.78) 0.79 1.09 (0.64 – 1.86) 0.76
CC+CG 85 142 1 1
GG 23 20 1.92 (1.00 – 3.71) 0.05 2.20 (1.08 – 4.47) 0.03
OR, odds ratio; CI, confidence interval.
basOR are adjusted for age and gender.BMC Cancer 2008, 8:359 http://www.biomedcentral.com/1471-2407/8/359
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I655V A>G and P1170A C>G of HER-2 gene are located in
the coding region that can affect protein structure and
enzyme activity. In our results, I655V A>G was not associ-
ated with the risk of lung cancer in the Korean population,
in consistance with previous study [16]. On the other
hand, P1170A C>G was related to the risk of lung cancer
in non-smokers and non-drinkers. These results suggest
that P1170A C>G polymorphism may influence the acti-
vation of HER-2 gene, affecting the binding activity of spe-
cific effector proteins in lung cancer. Indeed, a recent
review article describes several HER-2 binding partners
[32], and a previous report also showed that the substitu-
tion of amino acid residue in the functional domain of the
proteins can destabilize the protein-protein interactions
[33]. Further studies are needed to clearly elucidate the
relationship between the polymorphism and HER-2 acti-
vation.
To strengthen the significance of the present findings,
some further studies have to be performed. First, ethnic
difference of the polymorphisms of HER-2 gene should
more clearly be established, because some polymor-
phisms of genes including HER-2 have different distribu-
tion in multiethnic population [34,35]. Second, the
sample size of the subgroups of females, non-smokers and
non-drinkers should be increased.
Conclusion
Taken together, we conclude that the polymorphisms of
HER-2 gene do not play strong roles in lung cancer suscep-
tibility in the majority of the Korean population. How-
ever, we first demonstrated that the polymorphisms of
HER-2 gene are associated with increased risk of lung can-
cer within the subgroups of females, non-smokers and
non-drinkers in the Korean population. Our results can
contribute to understanding susceptibility of specific sub-
groups in lung cancer.
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